Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 4

Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors

,

Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.

EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
Now Viewing
EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer

Related Content:

Optimizing Therapy for Endometrial Cancer: Recent Data HighlightsNYU Langone's Perlmutter Cancer CenterInsightsGynecologic Oncology
Initial Approach to Management of RET-Positive NSCLC
Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets